利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

132 条记录 (耗时 0.078 秒)

    Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
    53.
    发明授权
    Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases 有权
    寡核糖核苷酸及其用于治疗脱发，急性肾衰竭和其它疾病的方法

    公开(公告)号：US08148342B2

    公开(公告)日：2012-04-03

    申请号：US12008578

    申请日：2008-01-11

    申请人： Elena Feinstein ,  Shai Ehrlich

    发明人： Elena Feinstein ,  Shai Ehrlich

    IPC分类号： A61K31/70

    CPC分类号： C12N15/1135 ,  C07H21/02 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/30

    摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.

    摘要翻译： 本发明涉及下调人p53基因表达的双链化合物，优选寡核糖核苷酸。 本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。 本发明还考虑了治疗患有脱发或急性肾功能衰竭或其它疾病的患者的方法，包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。 秃发可以通过化学疗法或放射疗法诱发，患者可能患有癌症，特别是乳腺癌。

    Screening systems utilizing RTP801
    55.
    发明授权
    Screening systems utilizing RTP801 有权
    使用RTP801的筛选系统

    公开(公告)号：US08034575B2

    公开(公告)日：2011-10-11

    申请号：US12800738

    申请日：2010-05-21

    申请人： Roni Wechsler ,  Igor Mett ,  Elena Feinstein

    发明人： Roni Wechsler ,  Igor Mett ,  Elena Feinstein

    IPC分类号： G01N33/53 ,  G01N33/566 ,  G01N33/567

    CPC分类号： G01N33/74 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2510/00

    摘要： RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801.The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors to and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.

    摘要翻译： RTP801代表缺氧诱导因子-1（HIF-1）的独特基因靶标。 通过缺氧对mTOR通路活性的下调需要从头mRNA的合成，并与RTP801的表达增加相关。 本发明涉及使用RTP801和/或RTP801相互作用体和/或RTP801生物学活性的筛选系统，由这种筛选系统鉴定的药物候选者，以及这些药物候选物在治疗各种疾病中的用途。

    OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES
    57.
    发明申请
    OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 有权
    用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法

    公开(公告)号：US20110201670A1

    公开(公告)日：2011-08-18

    申请号：US13092501

    申请日：2011-04-22

    申请人： Orna Mor ,  Elena Feinstein

    发明人： Orna Mor ,  Elena Feinstein

    IPC分类号： A61K31/713 ,  C07H21/02 ,  A61P27/02 ,  A61P27/12 ,  A61P9/10 ,  A61P9/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

    CPC分类号： C07H21/04 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76 ,  C12N9/1044 ,  C12N15/1137 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12Y203/02013 ,  C12N2310/3527 ,  C12N2310/3521

    摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.

    摘要翻译： 本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。 本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。 本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。 本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

    Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
    59.
    发明授权
    Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases 有权
    寡核糖核苷酸及其用于治疗纤维化病症和其它疾病的方法

    公开(公告)号：US07939652B2

    公开(公告)日：2011-05-10

    申请号：US12072941

    申请日：2008-02-28

    申请人： Orna Mor ,  Elena Feinstein

    发明人： Orna Mor ,  Elena Feinstein

    IPC分类号： C07H21/02 ,  C07H21/04 ,  A61K31/70 ,  C12Q1/68

    CPC分类号： C07H21/04 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76 ,  C12N9/1044 ,  C12N15/1137 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12Y203/02013 ,  C12N2310/3527 ,  C12N2310/3521

    摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.

    摘要翻译： 本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。 本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。 本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。 本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

    Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
    60.
    发明授权
    Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes 有权
    通过抑制促凋亡基因治疗或预防耳病

    公开(公告)号：US07825099B2

    公开(公告)日：2010-11-02

    申请号：US11655610

    申请日：2007-01-18

    申请人： Elena Feinstein

    发明人： Elena Feinstein

    IPC分类号： A61K48/00 ,  C12N15/63 ,  C07H21/02 ,  C07H21/04

    CPC分类号： A61K31/7088 ,  A61K31/70

    摘要： The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment (or balance impairment), particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

    摘要翻译： 本发明涉及一种或多种抑制剂，特别是siRNA，其下调人促凋亡基因的表达。 本发明还涉及包含化合物或能够表达化合物的载体和药学上可接受的载体的药物组合物。 本发明还考虑了治疗或预防听力损伤（或平衡障碍）的发生或严重性的方法，特别是与内耳毛细胞或外耳毛细胞的细胞死亡相关的听力损伤，包括向患者施用药物 组合物以治疗有效剂量，从而治疗患者。